Bevacizumab
Sarcopenia Affects Dose in Reinduction Therapy for Metastatic Colorectal Cancer
September 13, 2017Sarcopenia is significantly associated with dose reductions but not with dose-limiting toxicities at initiation of CAPOX-B reinduction therapy in patients with mCRC, researchers reported at ESMO 2017 Congress.
Adjuvant Bevacizumab Does Not Increase Survival in High-Risk Melanoma
June 05, 2017Five-year survival rate found similar to observation despite a significant improvement in disease-free interval.
No Serious HRQOL Decline With FOLFOXIRI/Bevacizumab
June 05, 2017Study compared FOLFOXIRI/bevacizumab and FOLFOX/bevacizumab in patients with metastatic colorectal cancer.
Personalized Medicine Approach Not Straightforward in Glioblastoma
June 05, 2016The role of antiangiogenic agents continues to evolve in the treatment of CNS cancers, attendees were told in a poster discussion session at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting.
Anticancer Drug Restores Hearing in Some Patients With Neurofibromatosis
April 05, 2016Durable hearing response was achieved in more than one-third of patients with neurofibromatosis type 2 and hearing loss treated with bevacizumab.
Biomarker May Predict Prognosis for Targeted Therapy in Patients With HER2-Negative Breast Cancer
September 30, 2015Brief exposure to a targeted therapy can tell doctors which patients with HER2-negative breast cancer will respond and which should switch to another kind of treatment.
Long-term outcomes improved by combining bevacizumab with newer chemotherapy regimen for advanced colorectal cancer
January 19, 2015A phase III study of patients with metastatic colorectal cancer has indicated that FOLFOXIRI chemotherapy, in combination with bevacizumab, is superior to the standard FOLFIRI chemotherapy with bevacizumab.
Bevacizumab-induced hypertension is a marker for improved outcomes in recurrent glioblastoma
December 31, 2014Researchers have found that bevacizumab-induced hypertension may be a predictive marker of improved outcomes in patients with recurrent glioblastoma who are treated with bevacizumab.
Impact of adding bevacizumab to presurgery chemotherapy for triple-negative breast cancer varies
December 26, 2014The addition of bevacizumab to standard presurgery chemotherapy showed greater benefit in those whose cancers were classified as basal-like by gene expression assay, compared with those whose cancers were nonbasal-like.
Bevacizumab promising for advanced cervical cancer
March 14, 2014Research has revealed that women with advanced cervical cancer live about 4 months longer with the combined use of bevacizumab and chemotherapy compared with chemotherapy alone.
Adjuvant bevacizumab increases cervical cancer survival
February 21, 2014Adjuvant bevacizumab increases overall survival in cervical cancer, and two studies show benefits of bevacizumab on PFS in newly diagnosed glioblastoma as well.
Bevacizumab promising in locally advanced cervical cancer
February 12, 2014A phase 2 trial of bevacizumab in addition to cisplatin and pelvic radiation for locally advanced cervical cancer found that adding bevacizumab to the existing standard of care showed promising overall results.
Resistance mechanism of colorectal cancer to bevacizumab detailed
November 18, 2013When colorectal cancer is targeted by the drug bevacizumab, tumors may switch dependence from VEGF-A (targeted by the drug) to related growth factors that include VEGF-C, VEGF-D, and placental growth factor.
Brain cancer survival is improved with bevacizumab
September 04, 2013A new study has found that patients with glioblastoma who died in 2010, after the FDA approved bevacizumab for the treatment of the deadly brain cancer, had lived significantly longer than patients who died prior to the conditional approval of the drug for this indication.
Test identifies which patients with glioblastoma are most likely to benefit from bevacizumab
June 21, 2013A new test may help identify which patients with newly diagnosed glioblastoma are more likely to benefit from bevacizumab.
Bevacizumab added to initial glioblastoma treatment does not extend lives
June 19, 2013Adding bevacizumab to initial treatment for glioblastoma did not improve overall patient survival or progression-free survival, according to results of a randomized phase III trial.
Time to tumor growth best predicts survival in colorectal cancer
May 20, 2013Time to tumor growth proved to be the best metric for predicting overall survival in persons with metastatic colorectal cancer on bevacizumab.
CT data help predict survival in metastatic melanoma
April 30, 2013Computerized tomography adds to lactate dehydrogenase (LDH) levels in predicting survival among persons with metastatic melanoma on bevacizumab.
Dasatinib thwarts brain cancer metastasis after bevacizumab use
March 01, 2013Combining the antiangiogenic bevacizumab with the kinase inhibitor dasatinib stopped glioblastoma metastasis after shrinking the tumors.
Bevacizumab prolongs life in ongoing trial of cervical cancer
February 21, 2013Bevacizumab plus chemotherapy improved survival in women with advanced, recurrent, or persistent cervical cancer, according to interim findings.
Bevacizumab approved in combination therapy for metastatic colorectal cancer
February 05, 2013The FDA has approved bevacizumab combined with other chemotherapy when metastatic colorectal cancer has progressed after first-line bevacizumab.
SABCS: Bevacizumab No Help in Triple-Negative Breast Cancer
December 07, 2012No significant improvement in invasive disease-free survival with bevacizumab plus chemo, according to a study.
Noninvasive technique predicts patients' response to chemotherapy
November 17, 2012Positron emission tomography (PET) can non-invasively predict how much of a cancer-killing drug is absorbed by a tumor. This preliminary study, conducted in lung cancer patients, found that less than 1% of docetaxel is absorbed by the tumors.
Noninvasive technique predicts patients' response to chemotherapy
November 17, 2012Positron emission tomography (PET) can non-invasively predict how much of a cancer-killing drug is absorbed by a tumor. This preliminary study, conducted in lung cancer patients, found that less than 1% of docetaxel is absorbed by the tumors.
Protein levels may predict if patients with colorectal cancer patients benefit from bevacizumab
November 02, 2012Patients with low levels of the protein VEGF165b who were treated with bevacizumab (Avastin) survived 3 months longer without their colorectal cancer progressing compared with patients not treated with the drug.
Radiosensitivity: A new focus on cardiovascular sequelae
June 01, 2012An increased risk of coronary artery stenosis in cancer survivors may be a long-term posttreatment effect of chest radiotherapy.
VEGF blockade: Optimizing chemotherapy drug uptake
April 17, 2012New research is showing that sequence and timing have significant impact on the efficacy of therapeutic regimens that include bevacizumab.
Bevacizumab delays return of ovarian cancer
January 13, 2012The use of bevacizumab (Avastin) improved progression-free survival in women with ovarian cancer, particularly those at high risk for disease progression.
LATE-BREAKING NEWS: FDA revokes Avastin breast cancer indication
November 18, 2011The FDA has revoked its approval of the breast cancer indication for Avastin (bevacizumab). The anti-angiogenic therapy remains indicated for some colorectal, lung, brain, and kidney cancers.
Bevacizumab label now warns of ovarian, osteonecrosis risks
October 12, 2011The FDA has announced labeling changes for bevacizumab (Avastin), indicated for the treatment of glioblastoma and colorectal, breast, kidney, and nonsquamous non-small cell lung cancers.
Sign Up for Free e-newsletters
ONA Articles
- Helping Patients Face the Challenge of Eating Healthy During Cancer Treatment
- Ixazomib Maintenance After ASCT Improves Progression-Free, Overall Survival in Multiple Myeloma
- Gastrointestinal Perforation Complicates Management of Mantle Cell Lymphoma
- Continuous Therapy May Be Beneficial in Patients With Newly Diagnosed Multiple Myeloma
- ASCO Convenes Panel to Address Handling of Hazardous Drugs
- Hormone Therapy for Breast Cancer (Fact Sheet)
- Counseling on the Dangers of Vaping
- Radical Prostatectomy vs Active Surveillance: Results of Nearly 3 Decades of Follow-up
- Potential of Fecal Microbiota Transplantation in Managing Immunotherapy-Associated Colitis
- Helping Patients Face the Challenge of Eating Healthy During Cancer Treatment
- Prevalence, Severity of Psychological Distress Higher in Patients Coping With Philadelphia-negative Myeloproliferative Neoplasm
- Biosimilar Cancer Treatment Ontruzant Gets FDA Approval
- Malignant Pleural Effusion Interventions: What Matters Most to the Patient?
- Ixazomib Maintenance After ASCT Improves Progression-Free, Overall Survival in Multiple Myeloma
- Evolutionary Role of Chemotherapy in Advanced Nasopharyngeal Carcinoma: A Literature-based Network Meta-analysis
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |